


## INT-767

<b>Cat. No.:</b>	HY-12434
<b>CAS No.:</b>	1000403-03-1
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>43</sub> NaO <sub>6</sub> S
<b>Molecular Weight:</b>	494.66
<b>Target:</b>	FXR; G protein-coupled Bile Acid Receptor 1; Autophagy
<b>Pathway:</b>	Metabolic Enzyme/Protease; GPCR/G Protein; Autophagy
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 100 mg/mL (202.16 mM)  
 H<sub>2</sub>O : 100 mg/mL (202.16 mM; Need ultrasonic)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
	1 mM		2.0216 mL	10.1080 mL	20.2159 mL
	5 mM		0.4043 mL	2.0216 mL	4.0432 mL
	10 mM		0.2022 mL	1.0108 mL	2.0216 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: PBS  
Solubility: 50 mg/mL (101.08 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (5.05 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (5.05 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (5.05 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

INT-767 is a dual farnesoid X receptor (FXR)/TGR5 agonist with mean EC<sub>50</sub>s of 30 and 630 nM, respectively<sup>[1][2]</sup>.

#### In Vitro

INT-767 does not show cytotoxic effects in HepG2 cells, does not inhibit cytochrome P450 enzymes, is highly stable to phase I and II enzymatic modifications, and does not inhibit the human ether-a-go-go-related gene potassium channel<sup>[2]</sup>.  
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## In Vivo

INT-767 (10-20 mg/kg; i.p.; daily for 2 weeks) decreases plasma total cholesterol and triglyceride levels in db/m and db/db mice [2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male 8-week old C57BKS/J db/db mice, control nondiabetic db/m mice <sup>[2]</sup>
Dosage:	10, 20 mg/kg
Administration:	Intraperitoneal injection; daily for 2 weeks
Result:	Decreased plasma total cholesterol and triglyceride levels.

## CUSTOMER VALIDATION

- J Am Soc Nephrol. 2018 Nov;29(11):2658-2670.
- Patent. US20200054589A1.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Baghdasaryan A, et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO<sub>3</sub><sup>-</sup> output. Hepatology. 2011 Oct;54(4):1303-1312.

[2]. Rizzo G, et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol Pharmacol. 2010 Oct;78(4):617-630.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA